Xinyuan Wang

Xinyuan Wang, Liang Wu, Yanjie Fu

Optimizing the presentation of search and recommendation results is crucial to enhancing user experience and engagement. Whole Page Optimization (WPO) plays a pivotal role in this process, as it directly influences how information is surfaced to users. While Pre-trained Large Language Models (LLMs) have demonstrated remarkable capabilities in generating coherent and contextually relevant content, fine-tuning these models for complex tasks like WPO presents challenges. Specifically, the need for extensive human-annotated data to mitigate issues such as hallucinations and model instability can be prohibitively expensive, especially in large-scale systems that interact with millions of items daily. In this work, we address the challenge of fine-tuning LLMs for WPO by using user feedback as the supervision. Unlike manually labeled datasets, user feedback is inherently noisy and less precise. To overcome this, we propose a reward-based fine-tuning approach, PageLLM, which employs a mixed-grained reward mechanism that combines page-level and item-level rewards. The page-level reward evaluates the overall quality and coherence, while the item-level reward focuses on the accuracy and relevance of key recommendations. This dual-reward structure ensures that both the holistic presentation and the critical individual components are optimized. We validate PageLLM on both public and industrial datasets. PageLLM outperforms baselines and achieves a 0.44\% GMV increase in an online A/B test with over 10 million users, demonstrating its real-world impact.

Ayush Noori, Joaquín Polonuer, Katharina Meyer et al.

Neurological diseases are the leading global cause of disability, yet most lack disease-modifying treatments. We present PROTON, a heterogeneous graph transformer that generates testable hypotheses across molecular, organoid, and clinical systems. To evaluate PROTON, we apply it to Parkinson's disease (PD), bipolar disorder (BD), and Alzheimer's disease (AD). In PD, PROTON linked genetic risk loci to genes essential for dopaminergic neuron survival and predicted pesticides toxic to patient-derived neurons, including the insecticide endosulfan, which ranked within the top 1.29% of predictions. In silico screens performed by PROTON reproduced six genome-wide $α$-synuclein experiments, including a split-ubiquitin yeast two-hybrid system (normalized enrichment score [NES] = 2.30, FDR-adjusted $p < 1 \times 10^{-4}$), an ascorbate peroxidase proximity labeling assay (NES = 2.16, FDR $< 1 \times 10^{-4}$), and a high-depth targeted exome sequencing study in 496 synucleinopathy patients (NES = 2.13, FDR $< 1 \times 10^{-4}$). In BD, PROTON predicted calcitriol as a candidate drug that reversed proteomic alterations observed in cortical organoids derived from BD patients. In AD, we evaluated PROTON predictions in health records from $n = 610,524$ patients at Mass General Brigham, confirming that five PROTON-predicted drugs were associated with reduced seven-year dementia risk (minimum hazard ratio = 0.63, 95% CI: 0.53-0.75, $p < 1 \times 10^{-7}$). PROTON generated neurological hypotheses that were evaluated across molecular, organoid, and clinical systems, defining a path for AI-driven discovery in neurological disease.